- Home
- MIRM vs LBTYB Comparison
MIRM vs LBTYB Comparison
Compare MIRM & LBTYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- LBTYB
- Stock Information
- Founded
- MIRM 2018
- LBTYB 2004
- Country
- MIRM United States
- LBTYB Bermuda
- Employees
- MIRM N/A
- LBTYB N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- LBTYB Cable & Other Pay Television Services
- Sector
- MIRM Health Care
- LBTYB Telecommunications
- Exchange
- MIRM Nasdaq
- LBTYB Nasdaq
- Market Cap
- MIRM 3.8B
- LBTYB 4.0B
- IPO Year
- MIRM 2019
- LBTYB N/A
- Fundamental
- Price
- MIRM $72.65
- LBTYB $11.00
- Analyst Decision
- MIRM Strong Buy
- LBTYB
- Analyst Count
- MIRM 11
- LBTYB 0
- Target Price
- MIRM $79.00
- LBTYB N/A
- AVG Volume (30 Days)
- MIRM 560.3K
- LBTYB 384.0
- Earning Date
- MIRM 11-04-2025
- LBTYB 01-01-0001
- Dividend Yield
- MIRM N/A
- LBTYB N/A
- EPS Growth
- MIRM N/A
- LBTYB N/A
- EPS
- MIRM N/A
- LBTYB N/A
- Revenue
- MIRM $429,161,000.00
- LBTYB $4,770,600,000.00
- Revenue This Year
- MIRM $53.14
- LBTYB $13.20
- Revenue Next Year
- MIRM $19.83
- LBTYB $1.75
- P/E Ratio
- MIRM N/A
- LBTYB N/A
- Revenue Growth
- MIRM 62.33
- LBTYB 48.52
- 52 Week Low
- MIRM $36.88
- LBTYB $9.15
- 52 Week High
- MIRM $78.55
- LBTYB $21.80
- Technical
- Relative Strength Index (RSI)
- MIRM 52.77
- LBTYB 47.62
- Support Level
- MIRM $68.34
- LBTYB $10.50
- Resistance Level
- MIRM $71.96
- LBTYB $12.60
- Average True Range (ATR)
- MIRM 2.53
- LBTYB 0.16
- MACD
- MIRM -0.13
- LBTYB -0.11
- Stochastic Oscillator
- MIRM 56.54
- LBTYB 19.69
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About LBTYB Liberty Global Ltd. Class B
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.